Trials / Terminated
TerminatedNCT03948763
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine the safety and tolerability and establish a preliminary recommended Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | V941 | V941 administered IM, Q3W for 9 3-week cycles |
| BIOLOGICAL | Pembrolizumab | Pembrolizumab 200 mg, IV for 35 3-week cycles |
Timeline
- Start date
- 2019-06-26
- Primary completion
- 2022-08-25
- Completion
- 2022-08-25
- First posted
- 2019-05-14
- Last updated
- 2025-01-28
- Results posted
- 2025-01-28
Locations
26 sites across 7 countries: United States, Australia, Hong Kong, New Zealand, Singapore, South Korea, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03948763. Inclusion in this directory is not an endorsement.